|
1
|
Rahn JJ, Dabbagh L, Pasdar M and Hugh JC:
The importance of MUC1 cellular localization in patients with
breast carcinoma: An immunohistologic study of 71 patients and
review of the literature. Cancer. 91:1973–1982. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Horm TM and Schroeder JA: MUC1 and
metastatic cancer. Expression, function and therapeutic targeting.
Cell Adh Migr. 7:187–198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh PK and Hollingsworth MA: Cell
surface-associated mucins in signal transduction. Trends Cell Biol.
16:467–476. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schroeder JA, Thompson MC, Gardner MM and
Gendler SJ: Transgenic MUC1 interacts with epidermal growth factor
receptor and correlates with mitogen activated protein kinase
activation in the mouse mammary gland. J Biol Chem.
276:13057–13064. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pochampalli MR, el Bejjani RM and
Schroeder JA: MUC1 is a novel regulator of ErbB1 receptor
trafficking. Oncogene. 26:1693–1701. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rahn JJ, Chow JW, Horne GJ, Mah BK,
Emerman JT, Hoffman P and Hugh JC: MUC1 mediates transendothelial
migration in vitro by ligating endothelial cell ICAM-1. Clin Exp
Metastasis. 22:475–483. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Regimbald LH, Pilarski LM, Longenecker BM,
Reddish MA, Zimmermann G and Hugh JC: The breast mucin MUCI as a
novel adhesion ligand for endothelial intercellular adhesion
molecule 1 in breast cancer. Cancer Res. 56:4244–4249.
1996.PubMed/NCBI
|
|
8
|
Li Q, Ren J and Kufe D: Interaction of
human MUC1 and beta-catenin is regulated by Lck and ZAP-70 in
activated Jurkat T cells. Biochem Biophys Res Commun. 315:471–476.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Kuwahara H, Ren J, Wen G and Kufe D:
The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1
carcinoma-associated antigen with GSK3 beta and beta-catenin. J
Biol Chem. 276:6061–6064. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Chen W, Ren J, Yu WH, Li Q, Yoshida
K and Kufe D: DF3/MUC1 signaling in multiple myeloma cells is
regulated by interleukin-7. Cancer Biol Ther. 2:187–193. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mukherjee P, Tinder TL, Basu GD and
Gendler SJ: MUC1 (CD227) interacts with lck tyrosine kinase in
Jurkat lymphoma cells and normal T cells. J Leukoc Biol. 77:90–99.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Al MA and Gendler SJ: Muc1 affects c-Src
signaling in PyV MT-induced mammary tumorigenesis. Oncogene.
24:5799–5808. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamamoto M, Bharti A, Li Y and Kufe D:
Interaction of the DF3/MUC1 breast carcinoma-associated antigen and
beta-catenin in cell adhesion. J Biol Chem. 272:12492–12494. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wei X, Xu H and Kufe D: MUC1 oncoprotein
stabilizes and activates estrogen receptor alpha. Mol Cell.
21:295–305. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ren J, Bharti A, Raina D, Chen W, Ahmad R
and Kufe D: MUC1 oncoprotein is targeted to mitochondria by
heregulin-induced activation of c-Src and the molecular chaperone
HSP90. Oncogene. 25:20–31. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raina D, Kharbanda S and Kufe D: The MUC1
oncoprotein activates the antiapoptotic phosphoinositide
3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol
Chem. 279:20607–20612. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee JJ, Loh K and Yap YS: PI3K/Akt/mTOR
inhibitors in breast cancer. Cancer Biol Med. 12:342–354.
2015.PubMed/NCBI
|
|
18
|
Castaneda CA, Cortes-Funes H, Gomez HL and
Ciruelos EM: The phosphatidyl inositol 3-kinase/AKT signaling
pathway in breast cancer. Cancer Metastasis Rev. 29:751–759. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chitnis MM, Yuen JS, Protheroe AS, Pollak
M and Macaulay VM: The type 1 insulin-like growth factor receptor
pathway. Clin Cancer Res. 14:6364–6370. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baselga J: Targeting the
phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Oncologist. 16 Suppl 1:S12–S19. 2011. View Article : Google Scholar
|
|
22
|
Ito K, Bernardi R and Pandolfi PP: A novel
signaling network as a critical rheostat for the biology and
maintenance of the normal stem cell and the cancer-initiating cell.
Curr Opin Genet Dev. 19:51–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirsch E, Ciraolo E, Ghigo A and Costa C:
Taming the PI3K team to hold inflammation and cancer at bay.
Pharmacol Ther. 118:192–205. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dowling RJO, Topisirovic I, Fonseca BD and
Sonenberg N: Dissecting the role of mTOR: Lessons from mTOR
inhibitors. Biochim Biophys Acta. 1804:433–439. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kenerson HL, Aicher LD, True LD and Yeung
RS: Activated mammalian target of rapamycin pathway in the
pathogenesis of tuberous sclerosis complex renal tumors. Cancer
Res. 62:5645–5650. 2002.PubMed/NCBI
|
|
26
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lippert B: Cisplatin: Chemistry and
biochemistry of a leading anticancer drug. Wiley-VCH; Basel: pp.
31999
|
|
28
|
Bielawski K, Bielawska A, Popławska B and
Bołkun-Skórnicka U: Synthesis, DNA-binding affinity and
cytotoxicity of the dinuclear platinum(II) complexes with berenil
and amines ligands. Acta Pol Pharm. 65:363–370. 2008.PubMed/NCBI
|
|
29
|
Barcelo F, Ortiz-Lombardia M and Portugal
J: Heterogeneous DNA binding modes of berenil. Biochim Biophys
Acta. 1519:175–184. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nguyen B, Hamelberg D, Bailly C, Colson P,
Stanek J, Brun R, Neidle S and Wilson WD: Characterization of a
novel DNA minor-groove complex. Biophys J. 86:1028–1041. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Czarnomysy R, Bielawski K, Muszynska A,
Bielawska A and Gornowicz A: Biological evaluation of
dimethylpyridine-platinum complexes with potent antiproliferative
activity. J Enzyme Inhib Med Chem. 31:150–165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bielawski K, Czarnomysy R, Muszyńska A,
Bielawska A and Popławska B: Cytotoxicity and induction of
apoptosis of human breast cancer cells by novel platinum(II)
complexes. Environ Toxicol Pharmacol. 35:254–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bielawska A, Popławska B, Surazyński A,
Czarnomysy R and Bielawski K: Cytotoxic efficacy of a novel
dinuclear platinum(II) complex in human breast cancer cells. Eur J
Pharmacol. 643:34–41. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bielawski K, Bielawska A, Popławska B,
Surazyński A and Czarnomysy R: The effect of a novel dinuclear
platinum complex with berenil and 2-picoline ligands on growth of
human breast cancer cells. Acta Pol Pharm. 67:609–614.
2010.PubMed/NCBI
|
|
35
|
Gornowicz A, Kałuża Z, Bielawska A,
Gabryel-Porowska H, Czarnomysy R and Bielawski K: Cytotoxic
efficacy of a novel dinuclear platinum(II) complex used with
anti-MUC1 in human breast cancer cells. Mol Cell Biochem.
392:161–174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pistritto G, Trisciuoglio D, Ceci C,
Garufi A and D'Orazi G: Apoptosis as anticancer mechanism: Function
and dysfunction of its modulators and targeted therapeutic
strategies. Aging (Albany NY). 8:603–619. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vousden KH and Lane DP: P53 in health and
disease. Nat Rev Mol Cell Biol. 8:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim HJ, Hawke N and Baldwin AS: NF-kappaB
and IKK as therapeutic targets in cancer. Cell Death Differ.
13:738–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dey N, Sun Y, Carlson JH, Wu H, Lin X,
Leyland-Jones B and De P: Anti-tumor efficacy of BEZ235 is
complemented by its anti-angiogenic effects via downregulation of
PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. Am J
Cancer Res. 6:714–746. 2016.PubMed/NCBI
|
|
40
|
Thomberry NA and Laxebnik Y: Caspases:
Enemies within. Science. 281:1312–1316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wei X, Xu H and Kufe D: Human MUC1
oncoprotein regulates p53-responsive gene transcription in the
genotoxic stress response. Cancer Cell. 7:167–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lutz W and Nowakowska-Swirta E: Gene p53
mutations, protein p53, and anti-p53 antibodies as biomarkers of
cancer process. Int J Occup Med Environ Health. 15:209–218.
2002.PubMed/NCBI
|
|
43
|
Abeysinghe RD, Greene BT, Haynes R,
Willingham MC, Turner J, Planalp RP, Brechbiel MW, Torti FM and
Torti SV: p53-independent apoptosis mediated by tachpyridine, an
anti-cancer iron chelator. Carcinogenesis. 22:1607–1614. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kosugi M, Ahmad R, Alam M, Uchida Y and
Kufe D: MUC1-C oncoprotein regulates glycolysis and pyruvate kinase
M2 activity in cancer cells. PLoS One. 6:e282342011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Raina D, Kosugi M, Ahmad R, Panchamoorthy
G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S
and Kufe D: Dependence on the MUC1-C oncoprotein in non-small cell
lung cancer cells. Mol Cancer Ther. 10:806–816. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Woo JK, Choi Y, Oh SH, Jeong JH, Choi DH,
Seo HS and Kim CW: Mucin 1 enhances the tumor angiogenic response
by activation of the AKT signaling pathway. Oncogene. 31:2187–2198.
2012. View Article : Google Scholar : PubMed/NCBI
|
